Document Detail

Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
MedLine Citation:
PMID:  20887614     Owner:  NLM     Status:  In-Process    
Several retrospective studies have raised concerns regarding digoxin therapy in select subgroups of heart failure patients. To assess the impact of digoxin therapy on outcomes in the current era of heart failure therapy, the authors analyzed data representing 5010 patients enrolled in the Valsartan Heart Failure Trial (Val-HeFT) to examine the relationship of baseline digoxin use and all-cause mortality, first morbid event, and heart failure hospitalizations. At baseline, 3374 patients (67%) were receiving digoxin therapy and 1636 (33%) were not. Patients receiving digoxin had features of worse heart failure with higher New York Heart Association class and lower blood pressure, ejection fraction, and β-blocker use (32.1% vs 40.8%). Digoxin use was associated with worse mortality (21.1 vs 15.0%, P<.001), first morbid event (34.6 vs 21.7, P<.001), and HF hospitalization rate (19.1 vs 10.1%, P<.001). After adjustment for baseline group differences including medical therapy and baseline rhythm, patients receiving digoxin remained at a higher risk for all-cause mortality (hazard ratio [HR], 1.28; 95% confidence interval [CI], 1.05-1.57), first morbid event (HR, 1.35; 95% CI, 1.15-1.59), and heart failure hospitalization (HR, 1.41; 95% CI, 1.12-1.78). These results remained materially unchanged with propensity matched analysis. No benefit with digoxin use was observed in this study, underscoring the need to reassess the role of digoxin in the contemporary management of heart failure.
Javed Butler; Inder S Anand; Michael A Kuskowski; Thomas Rector; Peter Carson; Jay N Cohn;
Related Documents :
10937954 - Neurohormonal reactivation in heart failure patients on chronic ace inhibitor therapy: ...
11790924 - Studies of prevention, treatment and mechanisms of heart failure in the aging spontaneo...
11863394 - Activation and release of degradative proteinases within the myocardium are the trigger...
12423714 - Effects of pentoxifylline on cytokine profiles and left ventricular performance in pati...
15537484 - Role of antiplatelet therapy in cardiovascular disease i: acute coronary syndromes.
656244 - Obstruction of right ventricular outflow tract by solitary ovarian metastasis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Congestive heart failure (Greenwich, Conn.)     Volume:  16     ISSN:  1751-7133     ISO Abbreviation:  Congest Heart Fail     Publication Date:    2010 Sep-Oct
Date Detail:
Created Date:  2010-10-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9714174     Medline TA:  Congest Heart Fail     Country:  United States    
Other Details:
Languages:  eng     Pagination:  191-5     Citation Subset:  IM    
Copyright Information:
© 2010 Wiley Periodicals, Inc.
Emory University, Atlanta, GA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Insights into the molecular requirements for the anti-obesity activity of a series of CB1 ligands.
Next Document:  Evaluation of 6 prognostic models used to calculate mortality rates in elderly heart failure patient...